Heparin Inhibits Retrovirus Binding to Fibronectin as Well as Retrovirus Gene Transfer on Fibronectin Fragments

ABSTRACT Fibronectin fragments have been shown to improve retrovirus gene transfer efficiency by binding retrovirus and target cells. Using a novel virus adhesion assay, we confirmed binding of type C oncoretrovirus vectors to the heparin II domain of fibronectin and demonstrated inhibition of viral binding and gene transfer by heparin.

[1]  D. Williams,et al.  Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. , 2000, Cancer research.

[2]  A. Elmaagacli,et al.  Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments. , 2000, Cytotherapy.

[3]  David A. Williams,et al.  Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells , 2000, Nature Medicine.

[4]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[5]  David A. Williams,et al.  Simultaneous Infection with Retroviruses Pseudotyped with Different Envelope Proteins Bypasses Viral Receptor Interference Associated with Colocalization of gp70 and Target Cells on Fibronectin CH-296 , 1999, Journal of Virology.

[6]  J. Rasko,et al.  Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. , 1998, Blood.

[7]  J. Nolta,et al.  Use of the bnx/hu xenograft model of human hematopoiesis to optimize methods for retroviral-mediated stem cell transduction (Review). , 1998, International journal of molecular medicine.

[8]  M. Wiznerowicz,et al.  Development of a double-copy bicistronic retroviral vector for human gene therapy. , 1998, Advances in experimental medicine and biology.

[9]  David A. Williams,et al.  Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. , 1997, Human gene therapy.

[10]  David A. Williams,et al.  Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy , 1996, Nature Medicine.

[11]  J. L. Le Doux,et al.  Proteoglycans secreted by packaging cell lines inhibit retrovirus infection , 1996, Journal of virology.

[12]  David A. Williams,et al.  Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. , 1996, Blood.

[13]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[14]  T. Barrowcliffe,et al.  Low anticoagulant heparin retains anti-HIV type 1 activity in vitro. , 1995, AIDS research and human retroviruses.

[15]  David A. Williams,et al.  Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. , 1994, The Journal of clinical investigation.

[16]  S. Orkin,et al.  Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34+ bone marrow cells. , 1993, Blood.

[17]  D. Williams,et al.  Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease , 1993, The Journal of experimental medicine.

[18]  D. Williams,et al.  Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane-bound and secreted forms of the human homolog of the steel gene product, stem cell factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Verfaillie,et al.  Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin , 1991, The Journal of experimental medicine.

[20]  K. Titani,et al.  Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. , 1991, Journal of biochemistry.

[21]  David A. Williams,et al.  Fibronectin and VLA-4 in haematopoietic stem cell–microenvironment interactions , 1991, Nature.

[22]  Kenneth M. Yamada,et al.  Fibronectin Domains and Receptors , 1989 .

[23]  S. Goff,et al.  Construction and use of a safe and efficient amphotropic packaging cell line. , 1988, Virology.

[24]  E. De Clercq,et al.  Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus , 1988, Antimicrobial Agents and Chemotherapy.

[25]  C. Kolvenbach,et al.  Evidence that binding to the carboxyl-terminal heparin-binding domain (Hep II) dominates the interaction between plasma fibronectin and heparin. , 1988, Biochemistry.

[26]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[27]  K. Simons,et al.  Transepithelial transport of a viral membrane glycoprotein implanted into the apical plasma membrane of Madin-Darby canine kidney cells. I. Morphological evidence , 1983, The Journal of cell biology.

[28]  E. Engvall,et al.  Fibronectin: purification, immunochemical properties, and biological activities. , 1982, Methods in enzymology.

[29]  E. Engvall,et al.  Alignment of biologically active domains in the fibronectin molecule. , 1981, The Journal of biological chemistry.

[30]  P. Vogt,et al.  Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. , 1969, Virology.